Naresh Gunaratnam, MD
Gastroenterology · Eagan, MNNPI 1194704486
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,348 of the $6,570 with a category attached, or 66.2%. Novo Nordisk accounts for 66.7% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $4,658, 3.2 times the $1,464 reported in 2019.
Across 17 payments — averaging $386.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Echosens North America, Inc.$1K
- US Endoscopy$250
- Regeneron Healthcare Solutions, Inc.$165
- AbbVie$130
- Pfizer$83
- plus $113 from 3 others
Across 410 payments — averaging $5064.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$833K
- AbbVie$523K
- Intercept Pharmaceuticals, Inc.$369K
- Takeda Pharmaceuticals U.S.A., Inc.$206K
- Janssen Research & Development, LLC$123K
- Intercept Pharma Europe Ltd.$18K
- plus $5K from 1 others
What the payments were for
- Consulting fees$2504%
- Speaking & faculty fees$4,34866%
- Travel & lodging$1,45022%
- Food & beverage$4827%
- Education$401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $4,380 |
| Echosens North America, Inc. | 1 | $1,450 |
| US Endoscopy | 1 | $250 |
| Regeneron Healthcare Solutions, Inc. | 2 | $165 |
| AbbVie | 1 | $130 |
| Pfizer | 7 | $83 |
| Cardinal Health 110 LLC | 1 | $78 |
| Lilly USA, LLC | 1 | $28 |
| Apollo Endosurgery US Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,570 in reported general payments places this provider in the 80th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Balsalazide Disodium | 21 | $5,590 |
| Ursodiol | 17 | $2,765 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 46 | $891 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $390 |
| Pantoprazole Sodium | 28 | $365 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 11 | $300 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Eagan
- Sajan NagpalEagan$46K
- John KisielRochester$856K
- Bradley CurrierSaint Cloud$470K
- Christopher GostoutRochester$299K
- Edward LoftusRochester$282K
- Alina AllenRochester$277K
- Todd BaronRochester$270K
- Sahil KhannaRochester$242K
- Joseph MurrayRochester$234K
- Andres AcostaRochester$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.